Refining the care of patients with pancreatic cancer: the AGITG Pancreatic Cancer Workshop consensus

Robert C Gandy, Andrew P Barbour, Jaswinder Samra, Mehrdad Nikfarjam, Koroush Haghighi, James G Kench, Payal Saxena and David Goldstein
Med J Aust 2016; 204 (11): . || doi: 10.5694/mja16.00061
Published online: 20 June 2016



  • A meeting of the Australasian Gastro-Intestinal Trials Group (AGITG) was held to develop a consensus statement defining when a patient with pancreatic cancer has disease that is clearly operable, is borderline, or is locally advanced/inoperable.
  • Key issues included the need for multidisciplinary team consensus for all patients considered for surgical resection. Staging investigations, to be completed within 4 weeks of presentation, should include pancreatic protocol computed tomography, endoscopic ultrasound, and, when possible, biopsy.
  • Given marked differences in outcomes, the operability of tumours should be clearly identified by categories: those clearly resectable by standard means (group 1a), those requiring vascular resection but which are clearly operable (group 1b), and those of borderline operability requiring vascular resection (groups 2a and 2b). Patients who may require vascular reconstruction should be referred, before exploration, to a specialist unit.
  • All patients should have a structured pathology report with standardised reporting of all seven surgical margins, which identifies an R0 (no tumour cells within a defined distance of the margin) if all surgical margins are clear from 1 mm.
  • Neo-adjuvant therapy is increasingly recommended for borderline operable disease, while chemotherapy is recommended as initial therapy for patients with unresectable loco-regional pancreatic cancer. The value of adding radiation after initial chemotherapy remains uncertain. A small number of patients may be downstaged by chemoradiation, and trimodality therapy should only be considered as part of a clinical trial.
  • Instituting these recommendations nationally will be an integral part of the process of improving quality of care and reducing geographic variation between centres in outcomes for patients.


  • Robert C Gandy1
  • Andrew P Barbour2
  • Jaswinder Samra3
  • Mehrdad Nikfarjam4
  • Koroush Haghighi1
  • James G Kench5
  • Payal Saxena5
  • David Goldstein1,6

  • 1 Prince of Wales Hospital, Sydney, NSW
  • 2 University of Queensland, Brisbane, QLD
  • 3 Royal North Shore Hospital, Sydney, NSW
  • 4 Austin Health, Melbourne, VIC
  • 5 Royal Prince Alfred Hospital, Sydney, NSW
  • 6 UNSW Prince of Wales Clinical School, Sydney, NSW



The AGITG received funding from the Avner Nahmani foundation, a charitable organisation devoted to improving survival of people with pancreatic cancer by funding research.

Competing interests:

David Goldstein is an unremunerated advisor to Bayer, Celgene, Amgen, Roche and Pfizer, and has received research funding for his institution from Celgene, Pfizer and Amgen. He is the treasurer and a board member of the AGITG. Andrew Barbour is an unremunerated advisor to Celgene and unpaid member of the AGITG Scientific Advisory Committee. The AGITG funded all travel.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.